Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus

Damien Blez, Marion Blaize, Carole Soussain, Alexandre Boissonnas, Aïda Meghraoui-Kheddar, Natacha Menezes, Anaïs Portalier, Christophe Combadière, Véronique Leblond, David Ghez, and Arnaud Fekkar

Disclosures: The Janssen Company supported the study. The data are the propriety of the Assistance publique - Hopitaux de Paris. The decision to publish these findings was made by the authors and not by the Janssen Company. The Janssen Company was not implicated in the writing of the manuscript. This work was supported by grants from Fondation pour la Recherche Medicale - Equipe labelisée and from Agence Nationale de la Recherche, project CMOS 2015 (ANR-EMMA-050). Other potential conflicts of interest: none for all authors.

Contributions: DB and MB performed experiments and participated in scientific discussions and writing of the paper; CS participated in the design of the study, scientific discussions and the inclusion of patients; AB participated in the design of flow cytometry analysis and microscopic experiments and participated in scientific discussions; AMK participated in the design of flow cytometry analysis and scientific discussions; NM performed experiments; AP participated in inclusion of patients; CC participated in scientific discussions; VL participated in the design of the study, scientific discussions and the inclusion of patients, DG participated in the design of the study, scientific discussions, inclusion of patients and wrote the paper; AF participated in the design of the study, designed all the experiments, performed experiments and wrote the paper.